References

1. Report of the Expert Committee on the Unification of Pharmacopoeias. Executive Board resolution EB7.R79, Geneva, World Health Organization, 1948.

2. The rational use of drugs. Report of the Conference of Experts. Nairobi, 25-29 November 1985. Geneva, World Health Organization, 1987.

3. Rational use of drugs. World Health Assembly resolution WHA41.16. Geneva, World Health Organization, 1988.

4. Counterfeit drugs report of a joint WHO/IFPMA Workshop. Geneva, World Health Organization, 1992 (unpublished document WHO/DMP/CFD/92).

5. Implementation of WHO'S revised drug strategy: Rational use of drugs; and WHO'S Action Programme on Essential Drugs. World Health Assembly resolution WHA47.13. Geneva, World Health Organization, 1994.

6. Assessment of the scale and problems of counterfeit drugs. Report of an informal consultation. Geneva, World Health Organization, 1995 (unpublished document).

7. WHO informal consultation on the use of simple test methods to detect counterfeit pharmaceutical products. Geneva, World Health Organization, 1995 (unpublished document PHARM/95.302).

8. Informal consultation on simple test methods and inspection aimed at detection of counterfeit pharmaceutical products. Geneva, World Health Organization (unpublished document DRS/QAS/95.1).

9. Report of the consultation on education and training of drug inspectors and drug analysts involved in the detection and eradication of counterfeit drugs. Geneva, World Health Organization, 1997 (unpublished document PHARM/97.353).

10. National implementation guidelines for combating counterfeit drugs, report of consultation. Geneva, World Health Organization, 1996 (unpublished draft document).

11. Report of the consultation on the progress and planning of the counterfeit drugs project. Geneva, World Health Organization, 1999 (unpublished document PHARM/99.405).

12. Counterfeit drugs, report of the international workshop on counterfeit drugs. Geneva, World Health Organization, 1997 (unpublished document WHO/DRS/CFD/98.1).

13. Report of the assessment of the problem of counterfeit drugs in Myanmar and Viet Nam: study carried out in cooperation with the Governments of Myanmar and Viet Nam. Geneva, World Health Organization, 1998 (unpublished document WHO/DAP/98.17).

14. Interregional workshop for decision makers in drug regulatory affairs and customs officials, Hanoi, Viet Nam. Geneva, World Health Organization, 1998 (unpublished draft document).

15. Report on the model training course for senior pharmaceutical inspectors on counterfeit drugs, Tokyo, Japan. Geneva, World Health Organization, 1998 (unpublished document).

16. Guidelines on the WHO certification scheme on the quality of pharmaceutical products moving in international commerce. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-fourth report. Geneva, World Health Organization, 1996, Annex 10 (WHO Technical Report Series No. 863).

17. Convention on Psychotropic Substances. New York, United Nations, 1971.

18. Single Convention on Narcotic Drugs (1961) as amended by the 1972 Protocol. New York, United Nations, 1977.

19. United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. New York, United Nations, 1988.

20. Guidelines on import procedures for pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization, 1996, Annex 12 (WHO Technical Report Series No. 863).

21. Guidelines for inspection of drug distribution channels. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 6 (WHO Technical Report Series No. 885).

22. Questionnaire for the assessment of nature and scale of counterfeit drugs. In: Assessment of the scale and problems of counterfeit drugs. Report of an informal consultation. Geneva, World Health Organization, 1995, Annex 3 (unpublished draft report).

23. Questionnaire for use in sample collection and investigation of samples. In: Assessment of the scale and problems of counterfeit drugs. Report of an informal consultation. Geneva, World Health Organization, 1995, Annex 4 (unpublished draft report).

24. Guidance for inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 6, Appendix 3 (WHO Technical Report Series No. 885).

25. Detection of counterfeit drugs and simple tests for pharmaceutical products. Geneva, World Health Organization, 1995 (unpublished document PHARM/95.299/rev. l).

26. Basic tests for pharmaceutical substances. Geneva, World Health Organization, 1986

27. Basic tests for pharmaceutical dosage forms. WHO, Geneva, World Health Organization, 1991.

28. Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms. WHO, Geneva, World Health Organization, 1998

29. Considerations on the use of simple test methods to detect counterfeit pharmaceutical products. In: Informal consultation on simple test methods and inspection aimed at detection of counterfeit pharmaceutical products. Geneva, World Health Organization, 1995, Annex 1 (unpublished document DRS/QAS/95.1).

30. Provisional guidelines for developing training programmes: inspection and examination of counterfeit pharmaceuticals. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 9 (WHO Technical Report Series No. 885).

31. Guiding principles for small national drug regulatory authorities. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-first report. Geneva, World Health Organization, 1990, Annex 6 (WHO Technical Report Series No. 790).

32. Sampling procedures for industrially manufactured pharmaceuticals. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-first report. Geneva, World Health Organization, 1990, Annex 2 (WHO Technical Report Series No. 790).

33. Role of the pharmacist in support of the WHO revised drug strategy. World Health Assembly resolution WHA47.12. Geneva, World Health Organization, 1994.

34. Implementation of WHO's revised drug strategy: Safety, efficacy and quality of pharmaceuticals. World Health Assembly resolution WHA47.17. Geneva, World Health Organization, 1994.

35. Developing protocols for changing in medical education. Geneva, World Health Organization, 1995 (unpublished document HRH/95.5).